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Abstract
Purpose: A method is presented to radiobiologically compare sequential (SEQ) and simultaneously integrated
boost (SIB) breast radiotherapy.
Methods: The method is based on identically prescribed biologically effective dose (iso-BED) which was achieved
by different prescribed doses due to different fractionation schemes. It is performed by converting the calculated
three-dimensional dose distribution to the corresponding BED distribution taking into consideration the different
number of fractions for generic α/β ratios. A cumulative BED volume histogram (BEDVH) is then derived from the
BED distribution and is compared for the two delivery schemes. Ten breast cancer patients (4 right-sided and
6 left-sided) were investigated. Two tangential intensity modulated whole breast beams with two other
oblique (with different gantry angles) beams for the boost volume were used. The boost and the breast
target volumes with either α/β = 10 or 3 Gy, and ipsi-lateral and contra-lateral lungs, heart, and contra-lateral
breast as organs at risk (OARs) with α/β = 3 Gy were compared.
Results: Based on the BEDVH comparisons, the use of SIB reduced the biological breast mean dose by about
3 %, the ipsi-lateral lung and heart by about 10 %, and contra-lateral breast and lung by about 7 %.
Conclusion: BED based comparisons should always be used in comparing plans that have different fraction
sizes. SIB schemes are dosimetrically more advantageous than SEQ in breast target volume and OARs for
equal prescribed BEDs for breast and boost.
Keywords: Breast cancer radiotherapy, Sequential boost (SEQ), Simultaneous integrated boost (SIB), Biologically
effective dose (BED), Biologically effective dose volume histogram (BEDVH)
Background
Adjuvant radiotherapy following breast conserving sur-
gery is still usually performed by homogenous irradiation
of the whole breast using doses of 1.8–2 Gy per fraction
up to a total dose of about 50 Gy, although hypofractio-
nated regimens are being used more and more often and
were shown to be well tolerated [1]. Frequently, a
sequential boost (SEQ) to the tumor bed follows, as it is
known to be the area of highest subclinical tumor cell
contamination [2]. Recently, many authors suggested the
use of simultaneously integrated boost (SIB) using doses
of 2.3–2.4 Gy to the tumor bed as it showed to be dosi-
metrically better, more convenient due to the shorter
treatment time and well tolerated [3, 4]. Moreover,
hypofractionation with SIB has been evaluated in a few
trials and appears to be feasible with no severe adverse
events [1, 3–6].
Starting from the linear-quadratic (LQ) model of cell
survival, Barendsen [7] introduced the extrapolated re-
sponse dose, which was later termed the biologically
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effective dose (BED) [8]. The BED concept has been
widely used in radiotherapy for conversion between differ-
ent fractionation schemes [8–10] and has become the
clinical reference tool to estimate the malignant and nor-
mal biological effects in tissues [11]. An alpha to beta ratio
(α/β) of 10 Gy for tumor response and α/β of 3 Gy for
late-responding normal tissues were used to determine
the SIB prescribed BED for the breast and the boost vol-
umes from the traditionally used SEQ prescribed BED
[12]. Recent reports suggest that healthy breast tissues as
well as the tumor are sensitive to fraction size with an α/β
of 5 Gy or less [13–15].
It is not an easy task to compare and assess two dose
distributions in terms of tumor control (TCP) and nor-
mal tissue complication (NTCP) probabilities, especially
when having different fractionation schedules. Many of
these comparisons are made by using dose volume histo-
grams (DVHs) [16, 17]. Different studies have shown a
disparity between the physical and biological dose distri-
bution [18, 19]. The biological effects do not depend
simply on the distribution of physical dose, but are a
non-linear function of the number and the size (dose) of
fractions [18, 19]. Therefore, using DVHs to compare or
evaluate two plans with different prescribed doses and
number of fractions could be misleading, as it does not
adequately represent the biological effect, even when
comparing two plans with the same prescribed biologic-
ally effective dose. The use of SIB techniques further
complicates the evaluation procedure, and puts an em-
phasis on the need to analyze the biological effectiveness
of the nominal dose based on the number of given frac-
tions. More recent studies suggest the use of LQ model
to interpret the DVH [18] and even to reduce the DVH
to a single biological parameter, such as equivalent uni-
form BED (EUBED) [20]. A method that incorporates all
biological parameters is demanded to radiobiologically
compare different treatment courses.
Here we present a novel method to rigorously compare
the biological effective doses of sequential and simultan-
eous integrated boost for breast cancer not only for the
prescribed BED but also for the 3D BED distribution for
target volumes and organs at risk (OARs) taking in con-
sideration different α/β values and number of fractions.
Materials and methods
Patient selection and image data
Ten female breast cancer patients (4 right-sided and 6
left-sided) treated in the Department of Radiation On-
cology, University Medical Center Mannheim/Germany
were retrospectively selected. Selection criteria were
average breast size with well-located tumor bed. The
planning computed tomography (CT) data-sets were ac-
quired with 5 mm slice thickness in supine position with
the use of a wing board for arm positioning above the
head by a CT-simulator (Brilliance CT Big Bore, Philips,
Cleveland, OH, USA).
Breast volumes include the total glandular breast tis-
sue cropped 4 mm inside the skin contour (the affected
side and the contra-lateral breast (CBreast)), the ipsi-
lateral lung (ILung), contra-lateral lung (CLung), and
heart were delineated. The tumor-bed was delineated by
an experienced radiation oncologist according to the
scar, pre- and post-operative radiological changes within
the breast tissue, the surgical report and/or the presence
of surgical clips. A setup safety margin of 5 mm was
automatically added to this tumor-bed to create the
boost planning target volume (PTVboost). This safety
margin was constrained to 5 mm under the skin con-
tour. The affected breast volume was considered the
whole breast planning target volume (PTVbreast).
Biologically effective dose (BED)
The concept of biologically effective dose (BED) is com-
monly used for iso-effective dose fractionation calculation
[9]. It is derived from the LQ model and is defined as:
BED ¼ nd 1þ d
α=β
 
ð1Þ
where n is the number of fractions, d is the dose per
fraction, and α/β is the ratio of the radiosensitivity
coefficients.
Using Eq. (1), the prescribed dose per fraction (d2) for
a different number of fractions n2 that is biologically iso-
effective can be calculated according to
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where BED is the chosen identically prescribed biologic-
ally effective dose (iso-BED).
Treatment planning and prescriptions
For each patient, a sequential boost (SEQ) and two sim-
ultaneously integrated boost (SIB) intensity modulated
radiotherapy (IMRT) plans were generated using a
Monaco treatment planning system (v3.3, Elekta AB,
Stockholm, Sweden).
The SEQ plans were composed of two different plans
that were optimized separately. The first plan was a
whole breast plan which consisted of two tangential
IMRT beams (medial and lateral tangents) assigned to
the PTVbreast with a prescription dose of 50 Gy in 25
fractions (BED = 60.0 Gy10 and 83.3 Gy3). The second
plan was the boost plan which consisted of two coplanar
IMRT oblique beams assigned to the PTVboost with indi-
vidually selected gantry angles to prevent any unneces-
sary dose to OARs especially the ipsi-lateral lung and
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contralateral breast. The prescribed dose for the boost
plan was 16 Gy to the PTVboost in 8 fractions (BED =
19.2 Gy10 and 26.7 Gy3) [21].
The SIB plans were achieved by combining the previ-
ously selected tangential beams assigned to the PTVbreast
and the two coplanar oblique beams assigned to the
PTVboost in a single optimized plan, i.e., the gantry an-
gles were the same for each patient as in the SEQ. The
first SIB plan (SIB10) was for prescribed doses of 2.3 Gy
to the PTVboost and 1.8 Gy to the PTVbreast in 28 frac-
tions, which correspond to total doses of 64.4 Gy and
50.4 Gy, respectively. The second SIB plan (SIB3) was
optimized for prescribed doses of 2.25 Gy to the
PTVboost and 1.84 Gy to the PTVbreast in 28 fractions,
which correspond to total doses of 62.9 Gy and 51.5 Gy,
respectively.
The optimization prescription aimed to deliver 95 % of
the prescribed dose to at least 95 % of the target vol-
umes and to minimize the volume receiving > 107 % of
the boost dose. Having reached these criteria, additional
effort was made to reduce dose to OARs individually for
each patient starting from the proper choice of gantry
angles to the fine-tuning of the prescription cost func-
tions. All plans were normalized to a median PTVboost
dose equal to the prescribed dose.
BED and BED-volume histogram (BEDVH)
The 3D dose distribution matrices of the SEQ plan (the
whole breast plan and the boost plan, separately) and
the two SIB plans for each patient were exported as
DICOM files. DICOM files were manipulated using
Computational Environment for Radiotherapy Research
(CERR) software [22]. The BED calculations were per-
formed using a code written in MATLAB (R2013a,
The MathWorks, Natick, MA). Each voxel dose was
converted to the corresponding BED using equation
(1) and taking into account the number of fractions
and the different α/β values for tumor and OARs. For
all OARs, α/β = 3 Gy was used in all plans. For
PTVbreast and PTVboost in SEQ plans, α/β = 10 Gy
and 3 Gy were used to calculate the BED (BED10 and
BED3); while in SIB10 and SIB3 plans BED10 and
BED3 were calculated, respectively.
Having converted the 3D dose matrices to 3D BED
matrices, cumulative BED volume histograms (BEDVH)
were generated and compared.
Statistical analysis
Descriptive statistics of the data are presented as mean ±
standard deviation (SD). The differences of the mean
BEDs between the two schemes were compared and ana-
lyzed using the two-tailed paired t test or the Wilcoxon
matched paired test using GraphPad Prism version 6.04
for Windows (GraphPad Software, La Jolla California
USA, www.graphpad.com). Statistically significant differ-
ences were assumed for a significance level of p <0.05.
Results
The PTVboost and PTVbreast volumes were (47 ± 27) cm
3
and (1124 ± 435) cm3, respectively. Table 1 presents the
beams angles and the PTVboost locations. Figures 1 and
2 show a CT image of a representative case with the
dose and the BED distribution of the sequential boost
plan and the simultaneous integrated boost plans. The
BED distributions were calculated using α/β = 3 Gy for
all OARs and either α/β = 10 Gy (in Fig. 1) or 3 Gy (in
Fig. 2) for target volumes in 28 fractions. The figures
demonstrate how the BED differs from the dose distri-
bution. In Fig. 1, and due to the difference in α/β
between target volumes and OAR, the maximum BED
values can be seen outside the target volumes concen-
trated in the lung and the rest of chest wall (red arrows).
The figures also demonstrate the advantages of the SIB
delivery scheme over the SEQ due to the improved
homogeneity in both dose and BED distribution. This
difference is due to the different prescribed doses and
because in SEQ plans the whole-breast and the boost
plans were optimized separately and then combined,
while in the SIB plans the four fields (two tangents for
the whole breast and two coplanar for boost) were opti-
mized simultaneously within a single plan.
Figure 3 presents the cumulative dose and BED volume
histograms of the sequential boost plan in comparison to
the simultaneously integrated boost plans using the same
prescribed biologically effective dose with α/β = 3 Gy for
all OARs and either α/β = 10 Gy or 3 Gy for boost and
breast target volumes in 28 fraction for the representative
case. The figure demonstrates the advantage of SIB plans
over the SEQ plans due to the reduction of the over-dose
outside the PTVboost that reduces the PTVbreast hot-spot
and ipsi-lateral organs mean doses. The figure shows also
that the BED is not a simple transformation of the struc-
ture’s dose where different (depending on the α/β) non-
linear scaling for the structure’s doses can be seen for the
two target volumes.
Table 1 Summary of beam angles used in both the sequential
boost (SEQ) and the simultaneous integrated boost (SIB)
schemes for the ten studied patients (mean ± SD)
Angle (°) Medial Tang Medial Boost Lateral Boost Lateral Tang
Left-sided a 308 ± 3 348 ± 3 111 ± 8 131 ± 3
Right-sided b 53 ± 4 21 ± 11 276 ± 21 229 ± 4
aGroup of 6 patients with left-sided breast tumor. PTVboost locations were
upper/outer quadrate, central quadrate, and lower/outer quadrate in three,
two, and one patient respectively
bGroup of 4 patients with right-sided breast tumor. PTVboost locations were
upper/outer quadrate, lower/outer quadrate, and upper/inner quadrate in two,
one, and one patient respectively
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Table 2 gives the comparison of the mean dose and
BED between the sequential boost plans and the simul-
taneous integrated boost plans for all structures of the
ten studied patients. The absolute and relative differ-
ences in the mean dose and BED between the two deliv-
ery schemes for all structures of the ten studied patients
are presented in Table 3. Both, PTVboost and PTVbreast
achieved a lower deviation from the prescribed BED in
the SIB cases (Table 2), reflecting improved performance
of optimization in one step compared to optimization in
two steps for the SEQ cases. The most relevant BED3
values for PTVbreast, ILung and Heartleft were signifi-
cantly (p <0.05) reduced in average by 2, 11 and 8 %, re-
spectively, thus demonstrating a better sparing of OARs
for the same, i.e., non-significantly different, BED in the
boost target volume. For the other OARs (Table 3) also
a reduction is seen, which however is not significant.
This could possibly be attributed to their larger distance
to the PTVboost and thus a smaller effect of the reduced
dose of the SIB plans. However, larger patient groups
Fig. 1 Dose (left column and BED (right column) distribution for a representative case using the sequential boost and the simultaneously
integrated boost schemes employing the same prescribed biologically effective dose with α/β = 3 Gy for all OARs and α/β = 10 Gy for target
volumes in 28 fractions. Due to the difference in α/β, the maximum BED values occur outside the target volumes (red arrows)
Fig. 2 Dose (left column) and BED (right column) distribution for a representative case using the sequential boost plan and the simultaneously
integrated boost plans employing the same prescribed biologically effective dose with α/β = 3 Gy for all OARs and target volumes in 28 fractions.
The PTVboost BED target coverage in the SIB plan is better than that of the SEQ plan (compare also Table 2)
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would probably render also this reduction as significant
as less total dose is applied to the PTVs (Table 3).
Discussion
The present study used the biologically effective dose
(BED) concept to compare the BED distribution between
the breast sequential boost and simultaneously integrated
boost schemes.
An iso-BED was calculated for the breast sequential
boost (SEQ) prescribed dose giving in 2 Gy per fraction
for 25 and 8 fractions for breast and boost target vol-
umes respectively for each of α/β = 10 (BED10) and 3
(BED3) Gy. Based on the iso-effective prescribed dose of
the sequential boost, the corresponding simultaneously
integrated boost (SIB) prescribed doses were calculated.
For each of ten breast patients, a SEQ IMRT plan and
two SIB IMRT plans (one for each of BED10 (SIB10) and
BED3 (SIB3)) were generated (Table 2). Corresponding
3D BED distributions were calculated. A comparison of
the BED distributions and mean structures’ BED between
the sequential and simultaneously integrated boost plans
were performed.
The results showed that the SIB schemes are better
than the SEQ schemes for PTVbreast (about 1 and 3 %),
ipsi-lateral OARs (about 8 and 10 %) and contra-lateral
OARs (about 6 and 7 %) in terms of dose and BED, re-
spectively (Table 3). It is also can be seen from the
smaller deviation of the mean values and the smaller
SDs of the SIB targets BEDs compared to the SEQ tar-
gets BEDs that the targets prescribed BEDs are better
achieved in SIB plans than in SEQ plans. Although the
dose reductions are in agreement with previously
Fig. 3 Cumulative dose (a and b) and BED (c and d) volume histograms of the representative case using sequential boost (solid line) and the
corresponding simultaneously integrated boost (dotted line) plans. The BED was calculated using the same prescribed biologically effective dose
with α/β = 3 Gy for OARs and α/β = 10 Gy (a and c) and 3 Gy (b and d) for boost and breast target volumes
Table 2 Comparison of mean dose and biologically effective dose (using either α/β = 10 Gy (BED10) or 3 Gy (BED3) for tumor
volumes and α/β = 3 Gy for all OARs) between sequential boost (SEQ) and the simultaneous integrated boost (SIB) schemes for all
structures of the ten studied patients (mean ± SD)
SEQ SIB10 SIB3
Dose (Gy) BED10 (Gy10) BED3 (Gy3) Dose (Gy) BED10 (Gy10) Dose BED3 (Gy3)
PTVboost Prescription 66.0 79.2 110.0 64.4 79.2 62.9 110.0
PTVbreast Prescription 50.0 60.0 83.3 50.4 60.0 51.5 83.3
PTVboost 65.7 ± 0.7 78.7 ± 1.0 109.2 ± 1.7 64.2 ± 0.1 78.9 ± 0.1 62.6 ± 0.1 109.4 ± 0.3
PTVbreast 53.4 ± 0.7 63.8 ± 0.8 88.0 ± 1.0 52.2 ± 0.4 61.9 ± 0.6 52.8 ± 0.5 86.2 ± 1.0
ILung 9.0 ± 1.8 12.2 ± 2.7 8.2 ± 1.7 11.0 ± 2.5 8.2 ± 1.6 10.9 ± 2.4
CBreast 1.2 ± 0.4 1.3 ± 0.4 1.1 ± 0.3 1.2 ± 0.3 1.1 ± 0.2 1.2 ± 0.3
CLung 1.0 ± 0.3 1.0 ± 0.4 0.9 ± 0.2 0.9 ± 0.3 0.9 ± 0.2 0.9 ± 0.2
Heart (Lt.) 3.4 ± 0.7 3.9 ± 1.1 3.0 ± 0.9 3.5 ± 1.2 3.2 ± 0.7 3.6 ± 1.0
Heart (Rt.) 2.3 ± 0.5 2.4 ± 0.6 1.9 ± 0.2 2.0 ± 0.2 2.0 ± 0.6 2.1 ± 0.6
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reported results [3, 12], when using the BEDVH concept
it becomes clear that biologically effective dose is consid-
erably reduced. The SIB and SEQ plans have the same
iso-BED, thus it is better to compare both plans based
on the corresponding BEDs instead on doses. This is
due to the difference between the fractionation that
leads to different biological effects. Based on the BED
comparisons, the SIB plans reduced the PTVbreast mean
BED by about 3 % (Table 3), the ipsi-lateral lung and
heart by about 10 %, and contra-lateral breast and lung
by about 7 %. About 0.3 Gy cardiac dose reduction is
reported in this study. One of the most current
population-based analyses has estimated a linear in-
crease in risk of major coronary events by 7.4 % for each
increase of 1 Gy in the mean radiation dose delivered to
the heart [23]. Therefore, we believe that the reported
difference in cardiac dose is meaningful. This improve-
ment is mainly due to the single step optimization of the
SIB plan, compared to the SEQ planning comprising two
separate steps for the breast and the boost plans. This
allows the optimization algorithm to account for the
dose from all fields in a one process and thus eliminate
the breast hot-spot and reduce the OARs doses.
In this analysis, a simple and more traditional tangen-
tial field arrangement was used. Although other multi-
field non-coplanar, IMRT or Volumetric Modulated Arc
Therapy (VMAT) techniques would improve the con-
formality and dose homogeneity within the target vol-
umes and may reduce OARs doses, our aim was to
demonstrate superiority of the SIB approach as a matter
of principle despite the use of simplified technique.
Therefore, it is essential to compare techniques which
differ only with respect to the planning algorithm, but
not the irradiation angles. The influence of the irradi-
ation technique is out of the scope of this study.
Recent clinical trials [1, 5, 6] were published proving the
feasibility and well-tolerated toxicity of hypofractionation
with SIB in early breast cancer. The comparison done here
was based on the BED and hence it is important to
consider the limitations of the LQ model and the
BED calculations. The LQ model does not take into
account the overall treatment time and potential volume
effect. This limitation may be important when comparing
treatment schemes differing on overall treatment time in
terms of acute toxicity [10, 18]. Therefore, the assumption
of overall treatment time independency may become
inaccurate when comparing widely different overall
treatment times such as in hypofractionated schemes
[1, 5, 6, 24]. Generally, it is considered that the limita-
tions of using the LQ model are mainly due to inaccuracies
of accounting for repopulation, bi-fractionated treatments
and high-dose fractions [25].
To account for variations due to uncertainty of α/β
ratio, two different α/β ratios (10 and 3 Gy) were used for
the tumor target volumes in the calculations of BED as
generic values to account for a range of expected values.
As the overall difference in the advantage for α/β = 10 Gy
compared to 3 Gy is relatively low (Table 3), our results
can be assumed representative also for other discussed
values, e.g., α/β = 4 Gy [14, 15]. Note that the selection of
two generic α/β ratios (10 Gy for target volumes and 3 Gy
for OARs) is the reason to see BED hot-spots outside the
target volumes (Fig. 1). This phenomenon appears when
neighboring structures have different α/β ratios and
results in a discontinuous BED distribution at the border
of the structures. Clearly, Fig. 2 with an α/β ratio of 3 Gy
for the breast tissue is more realistic.
Conclusion
Biologically effective dose comparison between sequential
and simultaneously integrated boost could be an import-
ant tool in plan evaluation and in understanding clinical
consequences of unconventional dose schedules. It helped
in demonstrating the advantages of the simultaneously
Table 3 Absolute and relative differences in mean dose and BED between sequential boost and the simultaneous integrated boost
using the same prescribed biologically effective dose with α/β = 10 Gy (BED10) and 3 Gy (BED3) for all structures of the ten studied
patients (mean ± SD)
Dose
(Gy)
(SIB10/SEQ–1) × 100 Dose
(Gy)
(SIB3/SEQ–1) × 100
Dose (%) BED10 (%) Dose (%) BED3 (%)
PTVboost −1.5 ± 0.7 −2 ± 1 0 ± 1 −3.0 ± 0.7 −5 ± 1 0 ± 2
PTVbreast −1.3 ± 0.8 −2 ± 1 −3 ± 1
a −0.6 ± 0.9 −1 ± 2 −2 ± 2 a
ILung −0.7 ± 0.4 −8 ± 4 −10 ± 4 a −0.8 ± 0.5 −9 ± 4 −11 ± 4 a
CBreast −0.1 ± 0.3 −6 ± 16 −6 ± 17 −0.1 ± 0.3 −5 ± 15 −6 ± 16
CLung −0.1 ± 0.1 −7 ± 13 −8 ± 14 −0.1 ± 0.2 −6 ± 17 −7 ± 18
Heartleft
b −0.3 ± 0.5 −10 ± 16 −12 ± 16 −0.2 ± 0.1 −6 ± 4 −8 ± 4 a
Heartright
c −0.3 ± 0.4 −12 ± 17 −14 ± 19 −0.2 ± 0.6 −8 ± 24 −10 ± 25
aIndicates a significant difference (p <0.05) between the SEQ and SIB plans in term of BED
bGroup of 6 patients with left-sided breast tumor
cGroup of 4 patients with right-sided breast tumor
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integrated boost for breast cancer in terms of breast target
volume and OARs doses.
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